Consumer healthcare has seen numerous innovations and expansions through digital services in 2020 . In particular, telehealth services have become a promising alternative to traditional or brick-and-mortar healthcare options, given restrictions brought on by this year's global pandemic. More clients are seeking at-home healthcare options with convenience and safety in mind.
The Health Care Technology Report (THCTR) has recognized Mindbloom founder Dylan Beynon as a Top 25 Consumer HealthTech Executive, acknowledging Mindbloom's role in expanding telehealth services to those seeking mental health treatment. He's joined by executives leading prominent digital healthcare companies such as Hims & Hers, Fitbit, Invisalign, and other innovators.
According to THCTR, "the awardees of 2020 have excelled in their field not only through deep expertise and determination but through the power of imagination and testing the limits of what is possible with technology. Hundreds of nominations were reviewed to arrive at this select set of executives. Each nominee was evaluated based on their career track record, reputation among peers and colleagues, experience in the industry, and company achievements, among other factors."
"The unique circumstances we faced in 2020 showed why digital healthcare innovation and continued expansion of telehealth services are so important. I'm honored to be named alongside such esteemed peers in consumer healthcare technology, " Beynon said, "Mindbloom's mission is to transform lives to transform the world, and I'm proud of Mindbloom's team and our ability to adapt quickly to become a fully virtual service in 2020, expanding access to psychedelic therapy modalities while continuing to improve outcomes for our clients."
This article is for informational purposes only and is not intended to be a substitute for professional medical advice. Always talk to your doctor about the risks and benefits of any treatment. If you are in a life-threatening situation, call the National Suicide Prevention Line at +1 (800) 273-8255, call 911, or go to the nearest emergency room.
Important FDA Safety Information
Ketamine is not FDA-approved for the treatment of depression or anxiety. Learn more about off-label uses here.
Side effects of ketamine treatment may include: altered sense of time, anxiety, blurred vision, diminished ability to see/hear/feel, dry mouth, elevated blood pressure or heart rate, elevated intraocular or intracranial pressure, excitability, loss of appetite, mental confusion, nausea/vomiting, nystagmus (rapid eye movements), restlessness, slurred speech, synesthesia (a mingling of the senses).
Do not proceed with ketamine treatment if any of the following apply to you:
- Allergic to ketamine
- Symptoms of psychosis or mania
- Uncontrolled high blood pressure
- CHF or other serious heart problem
- Severe breathing problem
- History of elevated intraocular or intracranial pressure
- History of hyperthyroidism
- Other serious medical illness
- Pregnant, nursing, or trying to become pregnant
Ketamine has been reported to produce issues including, but not limited to, those listed below. However, lasting adverse side-effects are rare when medical protocols are carefully followed.
While ketamine has not been shown to be physically addictive, it has been shown to cause moderate psychological dependency in some recreational users.
- In rare cases, frequent, heavy users have reported increased frequency of urination, urinary incontinence, pain urinating, passing blood in the urine, or reduced bladder size
- Ketamine may worsen problems in people with schizophrenia, severe personality disorders, or other serious mental disorders.
- Users with a personal or family history of psychosis should be cautious using any psychoactive substance, including ketamine, and discuss potential risks with your MindBloom clinician before proceeding with treatment.
- The dissociative effects of ketamine may increase patient vulnerability and the risk of accidents.
To promote positive outcomes and ensure safety, follow these ketamine treatment guidelines:
- Do not operate a vehicle (e.g., car, motorcycle, bicycle) or heavy machinery following treatment until you’ve had a full night of sleep
- Refrain from taking benzodiazepines or stimulants for 24 hours prior to treatment
- Continue to take antihypertensive medication as prescribed
- Avoid hangovers or alcohol intake
- Refrain from consuming solid foods within 3 hours prior to treatment and liquids within 1 hour prior to treatment
- Ketamine treatment should never be conducted without a monitor present to ensure your safety